Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.46 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.46 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27730601 | 0.89 | BCL9 (0.56) | BCL9CTNNB1MGLLKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL19668393 | 0.87 | LMNA (0.57) | BCL9CTNNB1KDM4EALDH1A1TDP1 | |
| SCHEMBL19668622 | 0.85 | KMT2A (0.58) | BCL9CTNNB1ALDH1A1TDP1POLB | |
| SCHEMBL22403127 | 0.84 | BCL9 (0.47) | BCL9CTNNB1MGLLKDM4EALDH1A1 | |
| SCHEMBL31584081 | 0.84 | BCL9 (0.52) | BCL9CTNNB1MGLLKDM4EALDH1A1 | |
| SCHEMBL31584076 | 0.84 | BCL9 (0.52) | BCL9CTNNB1MGLLKDM4EALDH1A1 | |
| SCHEMBL31377968 | 0.84 | KDM4E (0.59) | BCL9CTNNB1MGLLKDM4EALDH1A1 | |
| SCHEMBL22403177 | 0.83 | BCL9 (0.45) | BCL9CTNNB1MGLLKDM4EALDH1A1 | |
| SCHEMBL22403174 | 0.83 | BCL9 (0.48) | BCL9CTNNB1MGLLKDM4EALDH1A1 | |
| SCHEMBL31217940 | 0.83 | BCL9 (0.48) | BCL9CTNNB1MGLLKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
| EP-3474901-B1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B V (NL) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025106926-A1 | CONJUGATES TARGETING FIBROBLAST ACTIVATION PROTEIN AND USES THEREOF | Praxis Biotech LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025106939-A1 | CONJUGATES TARGETING FIBROBLAST ACTIVATION PROTEIN AND USES THEREOF | Praxis Biotech LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| US-12186405-B2 | Cleavable tetrazine used in bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2025-01-07 | — | — | US | disclosed |
| EP-4382167-A2 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | Tagworks Pharmaceuticals B.V. (NL) | 2024-06-12 | — | — | EP | disclosed |
| EP-3788032-B1 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | TAGWORKS PHARMACEUTICALS B V (NL) | 2024-01-24 | — | — | EP | disclosed |
| US-20230144534-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230144534-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| US-11617799-B2 | Cleavable tetrazine used in bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-04-04 | — | — | US | disclosed |
| US-20210308207-A1 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-10-07 | — | — | US | disclosed |
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-09-30 | — | — | US | disclosed |
| US-20190247513-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | BCL9 897/4885CTNNB1 258/4885MGLL 3372/4885 |
| US-20190247513-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | KIT, TPSB2, BTD | BCL9 3093/4885CTNNB1 1707/4885MGLL 3568/4885 |
| US-20230144534-A1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | KIT, TPSB2, BTD | BCL9 3102/4885CTNNB1 1687/4885MGLL 3571/4885 |
| US-11617799-B2 | Cleavable tetrazine used in bio-orthogonal drug activation | KIT, TPSB2, BTD | BCL9 3102/4885CTNNB1 1687/4885MGLL 3571/4885 |
| US-12186405-B2 | Cleavable tetrazine used in bio-orthogonal drug activation | KIT, TPSB2, BTD | BCL9 3102/4885CTNNB1 1687/4885MGLL 3571/4885 |
| US-20210299286-A1 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | FCER2, SQLE, TTL | BCL9 3987/4885CTNNB1 4053/4885MGLL 3728/4885 |
| US-20210308207-A1 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | VIP, PIN1, QPCT | BCL9 1607/4885CTNNB1 1671/4885MGLL 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.